Viewpoints: FDA Should Regulate Kratom, Not Ban It; Trauma And Its Physical Effect On The Body
Opinion writers weigh in on kratom, trauma, prescription drug costs and price transparency.
Stat:
Proposed Kratom Ban Would Harm The Public, Damage FDA's Credibility
Trust in the U.S. Food and Drug Administration (FDA) declined after its approval of the controversial Alzheimer’s drug aducanumab. Three experts resigned amid allegations that the FDA had caved to industry pressure. Some argue that its credibility has reached a new low. These events should have prompted the FDA to pause, reflect, and work to repair its reputation. Instead, the agency is forging ahead with actions that may further erode its credibility. A timely example is its position on Mitragyna speciosa, commonly called kratom, a tree related to coffee plants. (Mason Marks, 8/23)
The New York Times:
This Conversation Will Change How You Think About Trauma
“Trauma is much more than a story about something that happened long ago,” writes Dr. Bessel van der Kolk. “The emotions and physical sensations that were imprinted during the trauma are experienced not as memories but as disruptive physical reactions in the present.” (8/24)
The Star Tribune:
Here's How We'll Lower The Cost Of Prescription Drugs
"So here's a good idea … "That was the opening line of one of the first television ads I ran as a candidate for the U.S. Senate. The idea? Lowering prescription drug costs by allowing Medicare to negotiate the prices of drugs for seniors. Acting to stop skyrocketing drug prices still couldn't be more urgent. Many seniors have seen eye-popping price increases on many of the drugs they need to survive. In the past five years, the cost of Lyrica, a drug that treats nerve pain, increased 47%, while Symbicort, a medication for asthma and COPD, increased 46%, just to name a couple. And as a result, nearly 20% of older adults have reported not taking their medicines as prescribed because of the cost. (Amy Klobuchar, 8/23)
Stat:
Making CMS's Price Transparency Rule Work For All Stakeholders
The Centers for Medicare and Medicaid Services’ (CMS) price transparency rule requiring U.S. hospitals to provide clear, accessible pricing information online about the items and services they offer has been celebrated as a huge victory for patients. We think that celebration is premature as many hospitals are not fully complying with the rule more than eight months after it went into effect. (Chris Plance and Nilesh Chandra, 8/24)
